Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
Status:
Terminated
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
The study was being conducted in order to assess the pharmacokinetics and the safety of
elafibranor following once daily administration of two dose levels of elafibranor (80
milligrams [mg] and 120mg) during 3 months in children and adolescent population (8 to 17
years of age) with non alcoholic steatohepatitis (NASH).